Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: The plan, revealed by Illinois Department of Veterans’ Affairs Director Erica Jeffries at a legislative hearing in Chicago, comes after a pledge by the Republican governor less than two months ago that he would replace antiquated plumbing which could provide harbor for the bacteria that causes the deadly, pneumonia-like malady. Rauner did say at the time a newly constructed facility could be a long-term option. “The cost and the disruption and the construction that would be involved, not to mention the time it would take to do this (plumbing replacement) would just not be worth the effort when you think about building a brand-new building,” Jeffries said Monday. “We do not want to spend years tearing up 70-year-old buildings to put brand-new piping in when we know that might not be a total solution.” Rauner stayed at the home for a week in January to dramatize his efforts to get to the bottom of the outbreak. He has been pummeled by opponents in his re-election bid who say his administration’s response has mishandled the crisis. Jeffries, who did not cite a potential cost, said several of the buildings on the 130-year-old campus in western Illinois would be razed to make way for “state-of-the-art facilities” during the next three to five years. At another point Jeffries indicated that preliminary recommendations from task forces Rauner appointed would be delivered by March 31 with a final version due May 1. Rauner faces voters in a GOP primary election March 20. Rauner spokeswoman Rachel Bold said late Monday that plumbing replacement hasn’t been ruled out and noted that Rauner’s pronouncement in January included suggesting constructing a “brand-new building here that has the latest technology.” The administration installed a $6.5 million water-treatment plant, adopted rigorous plumbing-fixture flushing protocols, installed filters on fixtures, and treated water with heat and chemicals, among other steps, in its effort to stop the problem. After initially appearing in 2015, Legionnaire’s disease returned to the facility in 2016 and 2017. Four more cases were confirmed last month. Monday’s hearing was called after the administration released an August 2016 report from Belleville-based consulting engineer BRiC Partnership suggesting steps to mitigate the problem, including replacing the underground water-distribution system and plumbing inside 15 campus buildings where the most susceptible residents live for $8 million. Jeffries said in December that plumbing replacement could cost $500 million or more; in January, she told lawmakers the price tag was $25 million to $30 million, but didn’t specify the source of that estimate. She has never explained why she used estimates that at a minimum were more than four times higher than the actual number. BRiC’s 2016 report, which cost $20,000, listed about a dozen ideas for a total of $17 million. The administration paid BRiC another $40,000 to update and expand its 2016 report. That update released last month indicated plumbing replacement for the entire campus would be $11 million; expanded options for the other ideas combined would cost no more than $24 million. Jeffries explained Monday that the August 2016 delivery of the BRiC report was just two months after the June completion of a $6.5 million water-treatment facility and wanted to test its effectiveness before taking any more actions. But Public Health officials had confirmed two more cases of Legionnaires’ in late July, just days before BRiC’s arrival on campus. ___ Contact Political Writer John O’Connor at https://twitter.com/apoconnor . His work can be found at https://apnews.com/search/john%20o’connor ___ Sign up for the AP’s weekly newsletter showcasing our best reporting from the Midwest and Texas: http://apne.ws/2u1RMfv Claim: Rauner now plans to raze vet dorms where Legionnaires’ found.
Gov. Bruce Rauner’s administration announced on Monday that it plans to replace residence halls at the Quincy veterans’ facility which housed victims of a Legionnaires’ disease outbreak responsible for the deaths of 13 people and making dozens more ill since 2015.

Paragraph: The company said it will close the plant in Willowbrook, blaming “inaccurate and unfounded claims regarding Sterigenics and the unstable legislative and regulatory landscape in Illinois.” In August, nearly three dozen people sued Sterigenics, claiming fumes from ethylene oxide, used to sterilize medical equipment at the Willowbrook facility, have adversely affected their health. The Illinois Environmental Protection Agency closed the plant in February, finding that air sampling by town officials and the federal EPA consistently found high outdoor ambient levels of ethylene oxide. Federal regulators consider the gas a carcinogen. Sterigenics, in the past, has said ethylene oxide is the only process to sterilize medical instruments that is federally approved. “Sterigenics appreciates that the state of Illinois has clearly acknowledged the company’s consistent record of regulatory compliance as well as the safety of the new controls we agreed to implement, and we made every effort to reach a constructive resolution,” the company said in the statement announcing the plant’s closing, adding that Illinois’ political environment makes it unwise to operate the plant. Illinois House Republican leader, Rep. Jim Durkin, has been leading a fight against the company’s effort to continue operations outside Chicago. The Legislature is also considering measures that would phase out use of ethylene oxide except in less populated areas. “Sterigenics got the message that we were never going to let them reopen their doors and poison our communities again,” Durkin said in a statement. Illinois Attorney General Kwame Raoul and local officials in July reached an agreement with Sterigenics that would have allowed the plant to reopen after additional emission capture and control equipment was installed. Sterigenics also agreed to fund $300,000 in community projects designed in coordination with the state to benefit the environment and the local community. When that agreement was announced, company President Philip Macnabb said resolution of the matter puts the company a step closer to resuming the work of sterilizing vital medical products and devices for patients in Illinois and beyond. Sterigenics is a division of Ohio-based Sotera Health LLC, which provides safety services to the medical device, pharmaceutical, tissue and food industries. Claim: Chicago-area medical equipment cleaning plant won’t reopen.
Sterigenics, the medical supply sterilization company that has been battling lawsuits and claims of increased cancer rates from fumes, announced Monday it has decided against reopening its suburban Chicago plant.

Paragraph: "Highly anticipated data for a Gilead Sciences Inc (GILD.O) experimental antiviral drug are expected later this month. Analysts are also awaiting results in the near-term for products already approved for other conditions from companies such as Roche Holding (ROG.S) and Regeneron Pharmaceuticals (REGN.O). While experts estimate an approved vaccine could be at least a year away, progress toward treatments that benefit some COVID-19 patients could help investors gauge when the epidemic could come under control and some economic activity might  resume. “The more we see positive clinical data, the more investors will be comforted in the fact that this is a transitory issue like all epidemics are,” said Art Hogan, chief market strategist at National Securities. Early signs of a slowdown in hospitalizations and intensive care needs in coronavirus hotspots in the United States and abroad have fed a stock market turnaround sparked by massive support from the Federal Reserve and a more than $2 trillion government bailout. As of Monday, the S&P 500 .SPX was off about 21% from its Feb. 19 all-time high but had rebounded 19% since March 23. “With each incremental piece of good news, that gets us closer to the end of the epidemic and the economic damage that falls in its wake,” Hogan said. New York is nearing a plateau in the number of coronavirus patients hospitalized, Governor Andrew Cuomo said on Tuesday, even though the number of the deaths in the state hit a single-day high. Governments around the world have locked down their communities - urging citizens to stay inside and ordering restaurants, stores and other businesses shuttered - to contain the spread of COVID-19 cases, which have exceeded 1.4 million globally with over 80,000 deaths, according to a Johns Hopkins tally. Drugmakers are studying ways to combat the respiratory illness, for which there are no approved treatments, as hospitals face strains from the flood of patients. More than 330 clinical studies related to COVID-19 are listed in clinicaltrials.gov, a database maintained by the U.S. National Institutes of Health, including many seeking to test drugs already approved for other conditions. Gilead's remdesivir, which is administered intravenously, is one experimental treatment that has captured investors' attention. The biotechnology company's chief executive on March 28 said initial data would arrive in the ""coming weeks"" here and analysts said data could come in mid April. Remdesivir previously failed as a treatment for the Ebola virus. But it helped prevent disease and reduce severity of symptoms in monkeys infected with a virus more closely related to the new coronavirus in a study, raising hopes. Some analysts are cautioning against expecting that remdesivir will show an overwhelming benefit. Initial data are expected to come from studies of patients with relatively severe COVID-19. Because antivirals work best when patients are healthier, those results may show limited effectiveness, said Evan Seigerman, a biotech analyst at Credit Suisse. Even if remdesivir proves effective, the amount of the drug that would be available remains a concern. Gilead said last weekend here its existing supply could equate to more than 140,000 courses of treatment. Data is also anticipated for Regeneron (REGN.O) and Sanofi’s (SASY.PA) Kevzara, perhaps by the end of the month, and for Roche’s (ROG.S) Actemra - two similar rheumatoid arthritis drugs being tested for COVID-19 illness. Studies are also ongoing for hydroxychloroquine, a decades-old malaria drug that has been used by doctors for COVID-19 despite controversy over its effectiveness. “Just knowing that something works means investors can start thinking about the other side of this,” said Keith Lerner, chief market strategist at Truist/SunTrust Advisory Services, in emailed comments to Reuters, “both from a human side and an economic and market perspective.”" Claim: Investors await data on coronavirus drugs as market rally builds.

Clinical data on potential treatments for the new coronavirus could help sustain a market bounce that has buoyed stocks after last month’s plunge, as investors look for signs that authorities may be able to stabilize the pandemic.